| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/JGH.12519 |
| P698 | PubMed publication ID | 24476011 |
| P50 | author | Keqing Shi | Q59704601 |
| P2093 | author name string | Jian Gao | |
| De-Wei Li | |||
| Li Ying | |||
| Kai-Fu Tang | |||
| Yi-Jiang Song | |||
| Jian-Min Wu | |||
| Yu-Xiao Fang | |||
| Xue-Lian Zhu | |||
| Gui-Ling Li | |||
| Zhu-Jun Deng | |||
| Jun-Zhou Tang | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 |
| P433 | issue | 6 | |
| P921 | main subject | meta-analysis | Q815382 |
| liver disease | Q929737 | ||
| steatosis | Q1365091 | ||
| chronic liver disease | Q5113984 | ||
| P304 | page(s) | 1149-1158 | |
| P577 | publication date | 2014-06-01 | |
| P1433 | published in | Journal of Gastroenterology and Hepatology | Q15764401 |
| P1476 | title | Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy | |
| P478 | volume | 29 |
| Q38927192 | Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment |
| Q45070782 | Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. |
| Q40376800 | Coffee Intake Is Associated with a Lower Liver Stiffness in Patients with Non-Alcoholic Fatty Liver Disease, Hepatitis C, and Hepatitis B. |
| Q54760091 | Controlled Attenuation Parameter as a Noninvasive Method to Detect and Quantify Hepatic Steatosis in Chronic Liver Disease: What Is the Clinical Relevance? |
| Q30393929 | Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis |
| Q90223674 | Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis |
| Q64065840 | Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis |
| Q91740560 | Effect of Non-alcoholic Fatty Liver Disease on Transaminase Levels and Transient Elastography in Patients with Chronic Hepatitis B |
| Q41319267 | Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study |
| Q64092006 | Feasibility study and reference values of FibroScan 502 with M probe in healthy preschool children aged 5 years |
| Q98164597 | Hepatic steatosis and liver fat contents in liver transplant recipients are associated with serum adipokines and insulin resistance |
| Q48217549 | Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification. |
| Q33853664 | Medical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection. |
| Q92432581 | NON-INVASIVE ASSESSMENT OF LIVER STEATOSIS AND FIBROSIS USING TRANSIENT ELASTOGRAPHY AND CONTROLLED ATTENUATION PARAMETER IN TYPE 2 DIABETES PATIENTS |
| Q92900970 | New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode |
| Q38991269 | Non-invasive diagnosis of hepatic steatosis. |
| Q38635589 | Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)). |
| Q92829495 | Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension |
| Q90704875 | Predicting Hepatic Steatosis in Living Liver Donors Via Controlled Attenuation Parameter |
| Q93037833 | Prospective Evaluation of Hepatic Steatosis Using Ultrasound Attenuation Imaging in Patients with Chronic Liver Disease with Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard |
| Q91552287 | Quantitative Hepatic Fat Quantification in Non-alcoholic Fatty Liver Disease Using Ultrasound-Based Techniques: A Review of Literature and Their Diagnostic Performance |
| Q90746484 | Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease |
| Q33885985 | Risk Assessment of Hepatocellular Carcinoma in General Population by Liver Stiffness in Combination with Controlled Attenuation Parameter using Transient Elastography: A Cross Sectional Study |
| Q28831365 | Short-Term Hypocaloric High-Fiber and High-Protein Diet Improves Hepatic Steatosis Assessed by Controlled Attenuation Parameter |
| Q62060281 | The devil's triangle of steatosis, obesity, and liver stiffness |
| Q28084154 | Transient Elastography and Controlled Attenuation Parameter for Diagnosing Liver Fibrosis and Steatosis in Ontario: An Economic Analysis |
| Q26776180 | Transient Elastography for Assessment of Liver Fibrosis and Steatosis: An Evidence-Based Analysis |
| Q28079445 | Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? |
| Q33577504 | Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population |
| Q94093775 | UEG Week 2018 Poster Presentations |
| Q90737883 | Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference |
| Q33584964 | Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study |
| Q52990446 | [Ultrasound elastography]. |
Search more.